Bone Microarchitecture in Osteopenic Postmenopausal Women

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00577395
Recruitment Status : Terminated
First Posted : December 20, 2007
Results First Posted : December 22, 2009
Last Update Posted : April 22, 2013
Information provided by (Responsible Party):
Warner Chilcott

Brief Summary:
The purpose of this trial is to compare the difference in bone microarchitecture of the distal radius at month 12 in postmenopausal osteopenic women treated with risedronate 150mg taken once a month compared to placebo.

Condition or disease Intervention/treatment Phase
Osteoporosis Drug: placebo Drug: risedronate Phase 4

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 13 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A 12-month, Multicenter, Double-blind, Randomized, Parallel Group Study Comparing 150 mg Once-a-month Risedronate and Placebo Using 3-dimensional Micro MRI (Magnetic Resonance Imaging).
Study Start Date : July 2008
Actual Primary Completion Date : February 2009
Actual Study Completion Date : February 2009

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: 2
one 150 mg risedronate once a month, orally
Drug: risedronate
tablet, 150 mg once a month for 12 months
Placebo Comparator: 1
Placebo tablet once a month, orally
Drug: placebo
oral tablet once a month for 12 months

Primary Outcome Measures :
  1. Percent Change From Baseline in Erosion Index (A Ratio of Curve-like Structures to Plate-like Structures and is a Measure of the Degree of Structural Degradation) of the Distal Radius [ Time Frame: 12 months ]

    The percent was change from baseline in erosion index at the distal radius between the risedronate and placebo groups at Month 12 (the lower the percent change in erosion index, the greater the improvement of structural degradation); the last valid postbaseline measurement was to be used when the Month 12 value was missing (Last Observation Carried Forward or LOCF).

    NOTE: The study was unable to recruit sufficient numbers of patients to meet with the protocol specified numbers, thus it was terminated early after 5 months. No efficacy analyses were performed.

Secondary Outcome Measures :
  1. Erosion Index of the Distal Radius [ Time Frame: 6 months ]
    Study was terminated prior to acquiring any efficacy endpoints. No efficacy analyses were performed.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   40 Years to 57 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Female: 40 and 57 years of age inclusive
  • cessation of menstruation (surgical or natural) between 12 and 36 months prior to study enrollment
  • have osteopenia defines as having the following: have osteopenia defined as having the following:
  • Lumbar spine (L1-L4) Bone Mineral Density (BMD) T score -1 and less than -2.5 AND a total hip T score of greater than -2.5 OR
  • Lumbar spine (L1-L4) BMD T score greater than -2.5 AND a total hip T score -1 and less than -2.5;
  • have a body mass index (BMI) between 18 and 30 kg/m2.

Exclusion Criteria:

  • history of uncontrolled hyperparathyroidism, hyperthyroidism, osteomalacia
  • use of medications within 3 months of starting study drug that impact bone metabolism such as glucocorticoids, estrogens, calcitonin, calcitriol, other bisphosphonates and parathyroid hormone
  • hypocalcemia or hypercalcemia of any cause

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00577395

United States, Arizona
Research Facility
Tuscon, Arizona, United States, 85704
United States, Nebraska
Research Facility
Omaha, Nebraska, United States, 68729
United States, Ohio
Research Site
Cincinnati, Ohio, United States, 45201
Research Facility
Buenos Aires, Argentina
Sponsors and Collaborators
Warner Chilcott
Study Director: Ana M Balske, MD, PhD Procter and Gamble

Responsible Party: Warner Chilcott Identifier: NCT00577395     History of Changes
Other Study ID Numbers: 2007075
First Posted: December 20, 2007    Key Record Dates
Results First Posted: December 22, 2009
Last Update Posted: April 22, 2013
Last Verified: April 2013

Additional relevant MeSH terms:
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Metabolic Diseases
Risedronate Sodium
Etidronic Acid
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Bone Density Conservation Agents
Physiological Effects of Drugs